Teriparatide increases bone formation in modeling and remodeling osteons and enhances IGF-II immunoreactivity in postmenopausal women with osteoporosis

Journal of Bone and Mineral Research

Volumn 21, Issue 6, 2006, Pages 855-864

  Ma, Yanfei L ^a   Zeng, Qingqiang ^a   Donley, David W ^a   Ste Marie, Louis Georges ^b   Gallagher, J Christopher ^c   Dalsky, Gail P ^a   Marcus, Robert ^a   Eriksen, Erik Fink ^a  

^a ELI LILLY AND COMPANY   (United States)

^b UNIVERSITY OF MONTREAL   (Canada)

^c CREIGHTON UNIVERSITY   (United States)

Author keywords

Bone formation; Modeling; Osteoporosis; Teriparatide; Transiliac bone biopsy

Indexed keywords

PARATHYROID HORMONE[1-34]; PLACEBO; SOMATOMEDIN B; SOMATOMEDIN C;

ADULT; AGED; BONE BIOPSY; BONE REMODELING; CLINICAL ARTICLE; CLINICAL TRIAL; CONFERENCE PAPER; DOSE RESPONSE; FEMALE; HUMAN; HUMAN TISSUE; ILIAC BONE; IMMUNOLOCALIZATION; IMMUNOREACTIVITY; MORPHOMETRICS; OSSIFICATION; OSTEOPOROSIS; POSTMENOPAUSE; THICKNESS; TRABECULAR BONE;

AGED; BONE AND BONES; BONE DENSITY CONSERVATION AGENTS; BONE REMODELING; DEMOGRAPHY; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HAVERSIAN SYSTEM; HUMANS; IMMUNOHISTOCHEMISTRY; INSULIN-LIKE GROWTH FACTOR II; OSTEOGENESIS; OSTEOPOROSIS, POSTMENOPAUSAL; POSTMENOPAUSE; TERIPARATIDE;

EID: 33646871267     PISSN: 08840431     EISSN: None     Source Type: Journal    
DOI: 10.1359/jbmr.060314     Document Type: Conference Paper

References (52)

1. Parfitt AM, Mathews CH, Villanueva AR, Kleerekoper M, Frame B, Rao DS 1983 Relationships between surface, volume, and thickness of iliac trabecular bone in aging and in osteoporosis. Implications for the microanatomic and cellular mechanisms of bone loss. J Clin Invest 72:1396-1409.
2. NIH Consensus Development Panel 2001 Osteoporosis prevention, diagnosis, and therapy. JAMA 285:785-795.
3. Recker RR, Barger-Lux MJ 2004 The elusive concept of bone quality. Curr Osteoporos Rep 2:97-100.
4. Riggs BL, Parfitt AM 2005 Drugs used to treat osteoporosis: The critical need for a uniform nomenclature based on their action on bone remodeling. J Bone Miner Res 20:177-184.
5. Reeve J, Bradbeer JN, Arlot M, Davies UM, Green JR, Hampton L, Edouard C, Hesp R, Hulme P, Ashby JP 1991 hPTH 1-34 treatment of osteoporosis with added hormone replacement therapy: Biochemical, kinetic and histological responses. Osteoporos Int 1:162-170.
6. Hodsman AB, Fraher LJ, Ostbye T, Adachi JD, Steer BM 1993 An evaluation of several biochemical markers for bone formation and resorption in a protocol utilizing cyclical parathyroid hormone and calcitonin therapy for osteoporosis. J Clin Invest 91:1138-1148.
7. Hodsman AB, Fraher LJ, Watson PH, Ostbye T, Stitt LW, Adachi JD, Taves DH, Drost D 1997 A randomized controlled trial to compare the efficacy of cyclical parathyroid hormone versus cyclical parathyroid hormone and sequential calcitonin to improve bone mass in postmenopausal women with osteoporosis. J Clin Endocrinol Metab 82:620-628.
8. Eastell R, Delmas PD, Hodgson SF, Eriksen EF, Mann KG, Riggs BL 1988 Bone formation rate in older normal women: Concurrent assessment with bone histomorphometry, calcium kinetics, and biochemical markers. J Clin Endocrinol Metab 67:741-748.
9. Dobnig H, Sipos A, Jiang Y, Fahrleitner-Pammer A, Ste-Marie LG, Gallagher JC, Pavo I, Wang J, Eriksen EF 2005 Early changes in biochemical markers of bone formation correlate with improvements in bone structure during teriparatide therapy. J Clin Endocrinol Metab 90:3970-3977.
10. Arlot M, Meunier PJ, Boivin G, Haddock L, Tamayo J, Correa-Rotter R, Jasqui S, Donley DW, Dalsky GP, Martin JS, Eriksen EF 2005 Differential effects of teriparatide and alendronate on bone remodeling in postmenopausal women assessed by histomorphometric parameters. J Bone Miner Res 20:1244-1253.
11. Frost HM 1990 Skeletal structural adaptations to mechanical usage (SATMU): 1. Redefining Wolffs law: The bone modeling problem. Anat Rec 226:403-413.
12. Kobayashi S, Takahashi HE, Ito A, Saito N, Nawata M, Horiuchi H, Ohta H, Ito A, Iorio R, Yamamoto N, Takaoka K 2003 Trabecular minimodeling in human iliac bone. Bone 32:163-169.
13. Chavassieux PM, Arlot ME, Reda C, Wei L, Yates AJ, Meunier PJ 1997 Histomorphometric assessment of the long-term effects of alendronate on bone quality and remodeling in patients with osteoporosis. J Clin Invest 100:1475-1480.
14. Eriksen EF, Melsen F, Sod E, Barton I, Chines A 2002 Effects of long-term risedronate on bone quality and bone turnover in women with postmenopausal osteoporosis. Bone 31:620-625.
15. Neer RM, Arnaud CD, Zanchetta JR, Prince R, Gaich GA, Reginster JY, Hodsman AB, Eriksen EF, Ish-Shalom S, Genant HK, Wang O, Mitlak BH 2001 Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis. N Engl J Med 344:1434-1441.
16. Orwoll E, Scheele WH, Paul S, Adami S, Syversen U, Diez-Perez A, Kaufman JM, Clancy AD, Gaich G 2003 The effect of teriparatide [human parathyroid hormone (1-34)] therapy on bone mineral density in men with osteoporosis. J Bone Miner Res 18:9-17.
17. Jiang Y, Zhao JJ, Mitlak BH, Wang O, Genant HK, Eriksen EF 2003 Teriparatide [recombinant human parathyroid hormone (1-34)] improves both cortical and cancellous bone structure. J Bone Miner Res 18:1932-1941.
18. Dempster DW, Cosman F, Kurland ES, Zhou H, Nieves J, Woelfert L, Shane E, Plavetic K, Muller R, Bilezikian J, Lindsay R 2001 Effects of daily treatment with parathyroid hormone on bone microarchitecture and turnover in patients with osteoporosis: A paired biopsy study. J Bone Miner Res 16:1846-1853.
19. Seeman E, Delmas PD 2001 Reconstructing the skeleton with intermittent parathyroid hormone. Trends Endocrinol Metab 12:281-283.
20. Reeve J, Meunier PJ, Parsons JA, Bernat M, Bijvoet OL, Courpron P, Edouard C, Klenerman L, Neer RM, Renier JC, Slovik D, Vismans FJ, Potts JT Jr 1980 Anabolic effect of human parathyroid hormone fragment on trabecular bone in involutional osteoporosis: A multicentre trial. BMJ 280:1340-1344.
21. Bradbeer JN, Arlot ME, Meunier PJ, Reeve J 1992 Treatment of osteoporosis with parathyroid peptide (hPTH 1-34) and oestrogen: Increase in volumetric density of iliac cancellous bone may depend on reduced trabecular spacing as well as increased thickness of packets of newly formed bone. Clin Endocrinol (Oxf) 37:282-289.
22. Hodsman AB, Steer BM 1993 Early histomorphometric changes in response to parathyroid hormone therapy in osteoporosis: Evidence for de novo bone formation on quiescent cancellous surfaces. Bone 14:523-527.
23. Dempster DW, Zhou H, Cosman F, Nieves J, Adachi JD, Fraher LJ, Watson PH, Lindsay R, Hodsman AB 2001 PTH treatment directly stimulates bone formation in cancellous and cortical bone in humans. J Bone Miner Res 16:S1;S179.
24. Yao W, Jee WS, Zhou H, Lu J, Cui L, Setterberg R, Liang T, Ma Y 1999 Anabolic effect of prostaglandin E2 on cortical bone of aged male rats comes mainly from modeling-dependent bone gain. Bone 25:697-702.
25. Dobnig H, Turner RT 1995 Evidence that intermittent treatment with parathyroid hormone increases bone formation in adult rats by activation of bone lining cells. Endocrinology 136:3632-3638.
26. Hock JM, Hummert JR, Boyce R, Fonseca J, Raisz LG 1989 Resorption is not essential for the stimulation of bone growth by hPTH-(1-34) in rats in vivo. J Bone Miner Res 4:449-458.
27. Lindsay R, Cosman F, Zhou H, Bostrom MP, Shen VW, Cruz JD, Nieves JW, Dempster DW 2006 A novel tetracycline labeling scheduling for longitudinal evaluation of the short-term effects of anabolic therapy with a single iliac crest bone biopsy. Early actions of teriparatide. J Bone Miner Res 21:366-373.
28. Lindsay R, Nieves J, Formica C, Henneman E, Woelfert L, Shen V, Dempster D, Cosman F 1997 Randomised controlled study of effect of parathyroid hormone on vertebral-bone mass and fracture incidence among postmenopausal women on oestrogen with osteoporosis. Lancet 350:550-555.
29. Erben RG 1996 Trabecular and endocortical bone surfaces in the rat: Modeling or remodeling? Anat Rec 246:39-46.
30. Canalis E 1995 Growth hormone, skeletal growth factors and osteoporosis. Endocr Pract 1:39-43.
31. Yakar S, Rosen CJ, Beamer WG, Ackert-Bicknell CL, Wu Y, Liu JL, Ooi GT, Setser J, Frystyk J, Boisclair YR, LeRoith D 2002 Circulating levels of IGF-1 directly regulate bone growth and density. J Clin Invest 110:771-781.
32. Yakar S, Rosen CJ 2003 From mouse to man: Redefining the role of insulin-like growth factor-I in the acquisition of bone mass. Exp Biol Med (Maywood) 228:245-252.
33. Canalis E, McCarthy TL, Centrella M 1990 Differential effects of continuous and transient treatment with parathyroid hormone related peptide (PTHrp) on bone collagen synthesis. Endocrinology 126:1806-1812.
34. Kasukawa Y, Miyakoshi N, Mohan S 2004 The anabolic effects of GH/IGF system on bone. Curr Pharm Des 10:2577-2592.
35. Boonen S, Mohan S, Dequeker J, Aerssens J, Vanderschueren D, Verbeke G, Broos P, Bouillon R, Baylink DJ 1999 Downregulation of the serum stimulatory components of the insulin-like growth factor (IGF) system (IGF-I, IGF-II, IGF binding protein [BP]-3, and IGFBP-5) in age-related (type II) femoral neck osteoporosis. J Bone Miner Res 14:2150-2158.
36. Vahle JL, Sato M, Long GG, Young JK, Francis PC, Engelhardt JA, Westmore M, Ma L, Nold JB 2002 Skeletal changes in rats given daily subcutaneous injections of recombinant human parathyroid hormone(1-34) for 2 years and relevance to human safety. Toxicol Pathol 30:312-321.
37. Vahle JL, Long GG, Sandusky G, Westmore M, Ma YL, Sato M 2004 Bone neoplasms in F344 rats given teriparatide [rhPTH(1-34)] are dependent on duration of treatment and dose. Toxicol Pathol 32:426-438.
38. Eriksen EF 1986 Normal and pathological remodeling of human trabecular bone: Three dimensional reconstruction of the remodeling sequence in normals and in metabolic bone disease. Endocr Rev 7:379-408.
39. Parfitt AM, Drezner MK, Glorieux FH, Kanis JA, Malluche H, Meunier PJ, Ott SM, Recker RR 1987 Bone histomorphometry. Standardization of nomenclature, symbols, and units. Report of the ASBMR Histomorphometry Nomenclature Committee. J Bone Miner Res 2:595-610.
40. Ma Y, Jee WS, Chen Y, Gasser J, Ke HZ, Li XJ, Kimmel DB 1995 Partial maintenance of extra cancellous bone mass by antiresorptive agents after discontinuation of human parathyroid hormone (1-38) in right hindlimb immobilized rats. J Bone Miner Res 10:1726-1734.
41. Erben Reinhold G 1997 Embedding of bone samples in methymethacrylate: An improved method suitable for bone histomorphometry, histochemistry, and immunohistochemistry. J Histochem Cytochem 45:307-313.
42. Hodsman AB, Kisiel M, Adachi JD, Fraher LJ, Watson PH 2000 Histomorphometric evidence for increased bone turnover without change in cortical thickness or porosity after 2 years of cyclical hPTH(1-34) therapy in women with severe osteoporosis. Bone 27:311-318.
43. McClung MR, San Martin J, Miller PD, Civitelli R, Bandeira F, Omizo M, Donley DW, Dalsky GP, Eriksen EF 2005 Teriparatide and alendronate increase bone mass by opposite effects on bone remodeling. Arch Intern Med 165:1762-1768.
44. Misof BM, Roschger P, Cosman F, Kurland ES, Tesch W, Messmer P, Dempster DW, Nieves J, Shane E, Fratzl P, Klaushofer K, Bilezikian J, Lindsay R 2003 Effects of intermittent parathyroid hormone administration on bone mineralization density in iliac crest biopsies from patients with osteoporosis: A paired study before and after treatment. J Clin Endocrinol Metab 88:1150-1156.
45. Frost HM 1986 Intermediary Organization of the Skeleton. CRC Press, Boca Raton, FL, USA.
46. Eriksen EF, Mosekilde L, Melsen F 1986 Kinetics of trabecular bone resorption and formation in hypothyroidism: Evidence for a positive balance per remodeling cycle. Bone 7:101-108.
47. Mohan S, Baylink DJ 1991 Evidence that the inhibition of TE85 human bone cell proliferation by agents which stimulate cAMP production may in part be mediated by changes in the IGF-II regulatory system. Growth Regul 1:110-118.
48. Pepene CE, Seek T, Diel I, Minne HW, Ziegler R, Pfeilschifter J 2004 Influence of fluor salts, hormone replacement therapy and calcitonin on the concentration of insulin-like growth factor (IGF)-I, IGF-II and transforming growth factor-beta 1 in human iliac crest bone matrix from patients with primary osteoporosis. Eur J Endocrinol 150:81-91.
49. Turner CH 2002 Biomechanics of bone: Determinants of skeletal fragility and bone quality. Osteoporos Int 13:97-104.
50. Martin RB 2002 Size, structure and gender: Lessons about fracture risk. J Musculoskelet Neuronal Interact 2:209-211.
51. Seek T, Scheppach B, Scharla S, Diel I, Blum WF, Bismar H, Schmid G, Krempien B, Ziegler R, Pfeilschifter J 1998 Concentration of insulin-like growth factor (IGF)-I and -II in iliac crest bone matrix from pre- and postmenopausal women: Relationship to age, menopause, bone turnover, bone volume, and circulating IGFs. J Clin Endocrinol Metab 83:2331-2337.
52. Ishibe M, Ishibashi T, Kaneda K, Koda T, Rosier RN, Puzas JE 1998 Stimulation of bone formation in vivo by insulin-like growth factor-II in rats. Calcif Tissue Int 63:36-38.